Unmet needs of patients with narcolepsy: perspectives on emerging treatment options

References

• ThorpyMJDauvilliersYClinical and practical considerations in the pharmacologic management of narcolepsySleep Med201516191825458251
   PubMed Web of Science ®Google Scholar
• FrauscherBEhrmannLMitterlingTDelayed diagnosis, range of severity, and multiple sleep comorbidities: a clinical and polysomnographic analysis of 100 patients of the innsbruck narcolepsy cohortJ Clin Sleep Med20139880581223946711
   PubMed Web of Science ®Google Scholar
• International Classification of Sleep Disorders3rd edDarien, ILAmerican Academy of Sleep Medicine2014
   Google Scholar
• OvereemSMignotEvan DijkJGLammersGJNarcolepsy: clinical features, new pathophysiologic insights, and future perspectivesJ Clin Neurophysiol20011827810511435802
   PubMed Web of Science ®Google Scholar
• DauvilliersYArnulfIMignotENarcolepsy with cataplexyLancet2007369956049951117292770
   PubMed Web of Science ®Google Scholar
• OhayonMMPriestRGZulleyJSmirneSPaivaTPrevalence of narcolepsy symptomatology and diagnosis in the European general populationNeurology200258121826183312084885
   PubMed Web of Science ®Google Scholar
• ThorpyMJKriegerACDelayed diagnosis of narcolepsy: characterization and impactSleep Med201415550250724780133
   PubMed Web of Science ®Google Scholar
• DodelRPeterHSpottkeAHealth-related quality of life in patients with narcolepsySleep Med2007873374117512797
   PubMed Web of Science ®Google Scholar
• IngravalloFGnucciVPizzaFThe burden of narcolepsy with cataplexy: how disease history and clinical features influence socioeconomic outcomesSleep Med2012131293130023026503
   PubMed Web of Science ®Google Scholar
• JennumPIbsenRPetersenERKnudsenSKjellbergJHealth, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partnersSleep Med20121381086109322841027
   PubMed Web of Science ®Google Scholar
• JennumPKnudsenSKjellbergJThe economic consequences of narcolepsyJ Clin Sleep Med20095324024519960645
   PubMed Web of Science ®Google Scholar
• BroughtonWABroughtonRJPsychosocial impact of narcolepsySleep1994178 SupplS45S497701199
   PubMed Web of Science ®Google Scholar
• DanielsEKingMASmithIEShneersonJMHealth-related quality of life in narcolepsyJ Sleep Res2001101758111285058
   PubMed Web of Science ®Google Scholar
• PhilipPSagaspePLagardeESleep disorders and accidental risk in a large group of regular registered highway driversSleep Med20101197397920961809
   PubMed Web of Science ®Google Scholar
• NishinoSKotoriiNOverview of management of narcolepsyGoswamiMPandi-PerumalSRThorphyMJNarcolepsy: A Clinical GuideNew YorkSpringer2010251265
   Google Scholar
• MorgenthalerTIKapurVKBrownTStandards of Practice Committee of the American Academy of Sleep MedicinePractice parameters for the treatment of narcolepsy and other hypersomnias of central originSleep200730121705171118246980
   PubMed Web of Science ®Google Scholar
• PrinzmetalMBloombergWThe use of Benzedrine for the treatment of narcolepsyJAMA19351052520512054
   Google Scholar
• BermanSMKuczenskiRMcCrackenJTLondonEDPotential adverse effects of amphetamine treatment on brain and behavior: a reviewMol Psychiatry200914212314218698321
   PubMed Web of Science ®Google Scholar
• GuilleminaultCAmphetamines and narcolepsy: use of the Stanford databaseSleep19931631992018506450
   PubMed Web of Science ®Google Scholar
• MignotEJA practical guide to the therapy of narcolepsy and hypersomnia syndromesNeurotherapeutics20129473975223065655
   PubMed Web of Science ®Google Scholar
• MitlerMMHajdukovicRRelative efficacy of drugs for the treatment of sleepiness in narcolepsySleep19911432182201680245
   PubMed Web of Science ®Google Scholar
• BilliardMDauvilliersYDolenc-GrošeljLLammersGJMayerGSonkaKManagement of narcolepsy in adultsGilhusNEBarnesMBraininMEuropean Handbook of Neurological Management12nd edOxfordBlackwell Publishing2011513538
   Google Scholar
• DauvilliersYSiegelJMLopezRTorontaliZAPeeverJHCataplexy – clinical aspects, pathophysiology and management strategyNat Rev Neurol201410738639524890646
   PubMed Web of Science ®Google Scholar
• GuilleminaultCAftabFAKaradenizDPhilipPLegerDProblems associated with switch to modafinil – a novel alerting agent in narcolepsyEur J Neurol20007438138410971596
   PubMed Web of Science ®Google Scholar
• IzziFPlacidiFMarcianiMGEffective treatment of narcolepsy-cataplexy with duloxetine: a report of three casesSleep Med200910115315418226953
   PubMed Web of Science ®Google Scholar
• ZvosecDLSmithSWPorrataTStroblAQDyerJECase series of 226 γ-hydroxybutyrate-associated deaths: lethal toxicity and traumaAm J Emerg Med201129331933220825811
   PubMed Web of Science ®Google Scholar
• McDonnellKNarcolepsy patient community prepares to share life impacts, treatment perspectives with FDA regulators [press release]Worcester, MAWake Up Narcolepsy, Inc2013919 Available from: http://www.wakeupnarcolepsy.org/press-releasenarcolepsy-patient-community-prepares-share-life-impacts-treatment-perspectives-fda-regulatorsAccessed March 20, 2015
   Google Scholar
• ShneersonJMDauvilliersYAPlazziGMyersAJGarcia-BorregueroDThe impact of narcolepsy and its treatment – a European studyEur Neurol Rev200832105108
   Google Scholar
• ThorpyMZhaoCGDauvilliersYManagement of narcolepsy during pregnancySleep Med201314436737623433999
   PubMed Web of Science ®Google Scholar
• HasegawaEYanagisawaMSakuraiTMiedaMOrexin neurons suppress narcolepsy via 2 distinct efferent pathwaysJ Clin Invest2014124260461624382351
   PubMed Web of Science ®Google Scholar
• BourginPHuitrón-RésendizSSpierADHypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neuronsJ Neurosci200020207760776511027239
   PubMed Web of Science ®Google Scholar
• HuangZLQuWMLiWDArousal effect of orexin A depends on activation of the histaminergic systemProc Natl Acad Sci U S A200198179965997011493714
   PubMed Web of Science ®Google Scholar
• XiMCMoralesFRChaseMHEffects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the catBrain Res20019011–225926411368975
   PubMed Web of Science ®Google Scholar
• MiedaMWillieJTHaraJSintonCMSakuraiTYanagisawaMOrexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in miceProc Natl Acad Sci U S A2004101134649465415070772
   PubMed Web of Science ®Google Scholar
• ThompsonMDXhaardHSakuraiTRaineroIKukkonenJPOX1 and OX2 orexin/hypocretin receptor pharmacogeneticsFront Neurosci201485724834023
   PubMed Web of Science ®Google Scholar
• MishimaKFujikiNYoshidaYHypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsySleep20083181119112618714784
   PubMed Web of Science ®Google Scholar
• FujikiNYoshidaYRipleyBMignotENishinoSEffects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dogSleep200326895395914746374
   PubMed Web of Science ®Google Scholar
• JohnJWuMFSiegelJMSystemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogsSleep Res Online200031232811382896
   PubMedGoogle Scholar
• HansonLRFreyWH2ndIntranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative diseaseBMC Neurosci20089Suppl 3S519091002
   PubMed Web of Science ®Google Scholar
• DhuriaSVHansonLRFreyWH2ndNovel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous systemJ Pharmacol Exp Ther2009328131232018945930
   PubMed Web of Science ®Google Scholar
• DeadwylerSAPorrinoLSiegelJMHampsonRESystemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primatesJ Neurosci20072752142391424718160631
   PubMed Web of Science ®Google Scholar
• BaierPCWeinholdSLHuthVGottwaldBFerstlRHinze-SelchDOlfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal orexin a (hypocretin-1)Brain2008131Pt 102734274118718966
   PubMed Web of Science ®Google Scholar
• BaierPCHallschmidMSeeck-HirschnerMEffects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexySleep Med2011121094194622036605
   PubMed Web of Science ®Google Scholar
• LammersGJIntranasal hypocretin-1: making sense of scents?Sleep Med2011121093994022136855
   PubMed Web of Science ®Google Scholar
• WeinholdSLSeeck-HirschnerMNowakAHallschmidMGöderRBaierPCThe effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexyBehav Brain Res201426281324406723
   PubMed Web of Science ®Google Scholar
• SunHKennedyWPWilbrahamDEffects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy menSleep201336225926723372274
   PubMed Web of Science ®Google Scholar
• BossCOrexin receptor antagonists – a patent review (2010 to August 2014)Expert Opin Ther Pat201424121367138125407283
   PubMed Web of Science ®Google Scholar
• HeifetzABarkerOMorrisGBLawRJSlackMBigginPCToward an understanding of agonist binding to human orexin-1 and orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesisBiochemistry201352468246826024144388
   PubMed Web of Science ®Google Scholar
• Arias-CarriónOMurillo-RodríguezEEffects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in ratsPLoS One201494e9534224736646
   PubMed Web of Science ®Google Scholar
• StayteSVisselBAdvances in non-dopaminergic treatments for Parkinson’s diseaseFront Neurosci2014811324904259
   PubMed Web of Science ®Google Scholar
• LiuMThankachanSKaurSOrexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in miceEur J Neurosci2008281382139318973565
   PubMed Web of Science ®Google Scholar
• LiuMBlanco-CenturionCKonadhodeROrexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic miceJ Neurosci2011316028604021508228
   PubMed Web of Science ®Google Scholar
• Blanco-CenturionCLiuMKonadhodeRPelluruDShiromaniPJEffects of orexin gene transfer in the dorsolateral pons in orexin knockout miceSleep2013361314023288969
   PubMed Web of Science ®Google Scholar
• HaasHLSergeevaOASelbachOHistamine in the nervous systemPhysiol Rev20088831183124118626069
   PubMed Web of Science ®Google Scholar
• LinJSSergeevaOAHaasHLHistamine H3 receptors and sleep-wake regulationJ Pharmacol Exp Ther20113361172320864502
   PubMed Web of Science ®Google Scholar
• NishinoSSakuraiENevsimalovaSDecreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controlsSleep200932217518019238804
   PubMed Web of Science ®Google Scholar
• De la Herrán-AritaAKGarcía-GarcíaFCurrent and emerging options for the drug treatment of narcolepsyDrugs201373161771178124122734
   PubMed Web of Science ®Google Scholar
• SchwartzJCThe histamine H3 receptor: from discovery to clinical trials with pitolisantBr J Pharmacol2011163471372121615387
   PubMed Web of Science ®Google Scholar
• LinJSDauvilliersYArnulfIAn inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/-mice and patientsNeurobiol Dis2008301748318295497
   PubMed Web of Science ®Google Scholar
• InocenteCArnulfIBastujiHPitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepinessClin Neuropharmacol2012352556022356925
   PubMed Web of Science ®Google Scholar
• DauvilliersYBassettiCLammersGJHARMONY I study groupPitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trialLancet Neurol201312111068107524107292
   PubMed Web of Science ®Google Scholar
• KaupmannKCryanJFWellendorphPSpecific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient miceEur J Neurosci200318102722273014656321
   PubMed Web of Science ®Google Scholar
• VienneJBettlerBFrankenPTaftiMDifferential effects of GABAB receptor subtypes, {gamma}-hydroxybutyric acid, and baclofen on EEG activity and sleep regulationJ Neurosci20103042141941420420962240
   PubMed Web of Science ®Google Scholar
• HuangYSGuilleminaultCNarcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybatePediatr Neurol200941191619520267
   PubMed Web of Science ®Google Scholar
• BlackSWMorairtySRChenTMGABAB agonism promotes sleep and reduces cataplexy in murine narcolepsyJ Neurosci201434196485649424806675
   PubMed Web of Science ®Google Scholar
• FryeREClinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorderDrug Healthc Patient Saf20146697624872724
   PubMedGoogle Scholar
• KolesnickRNGershengornMCThyrotropin-releasing hormone and the pituitary. New insights into the mechanisms of stimulated secretion and clinical usageAm J Med19857967297392416218
   PubMed Web of Science ®Google Scholar
• NillniEARegulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by neuronal and peripheral inputsFront Neuroendocrinol201031213415620074584
   PubMed Web of Science ®Google Scholar
• SunYZupanBRaakaBMTothMGershengornMCTRH-receptor-type-2-deficient mice are euthyroid and exhibit increased depression and reduced anxiety phenotypesNeuropsychopharmacology20093461601160819078951
   PubMed Web of Science ®Google Scholar
• Van den BerghPOctaveJNLechanRMMuscle denervation increases thyrotropin-releasing hormone (TRH) biosynthesis in the rat medullary rapheBrain Res19915661–22192241814539
   PubMed Web of Science ®Google Scholar
• EtoKKimSKNabekuraJIshibashiHTaltirelin, a thyrotropin-releasing hormone analog, alleviates mechanical allodynia through activation of descending monoaminergic neurons in persistent inflammatory painBrain Res20111414505721872219
   PubMed Web of Science ®Google Scholar
• HoritaAAn update on the CNS actions of TRH and its analogsLife Sci199862144314489585116
   PubMed Web of Science ®Google Scholar
• LechanRMFeketeCThe TRH neuron: a hypothalamic integrator of energy metabolismProg Brain Res200615320923516876577
   PubMed Web of Science ®Google Scholar
• DaimonCMChirdonPMaudsleySMartinBThe role of thyrotropin releasing hormone in aging and neurodegenerative diseasesAm J Alzheimers Dis (Columbia)201311
   Google Scholar
• PittsLHRossAChaseGAFadenAITreatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuriesJ Neurotrauma19951232352437473798
   PubMed Web of Science ®Google Scholar
• KellyJABoyleNTColeNFirst-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative modelsNeuropharmacology20158919320325281210
   PubMed Web of Science ®Google Scholar
• KamathJFeinnRWinokurAThyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled studySupport Care Cancer20122081745175321947558
   PubMed Web of Science ®Google Scholar
• SahNRajputSKSinghJNL-pGlu-(2-propyl)-L-His-L-ProNH2 attenuates 4-aminopyridine-induced epileptiform activity and sodium current: a possible action of new thyrotropin-releasing hormone analog for its anticonvulsant potentialNeuroscience2011199748522037285
   PubMed Web of Science ®Google Scholar
• KatoZOkudaMOkumuraYOral administration of the thyrotropin-releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophyJ Child Neurol20092481010101219666885
   PubMed Web of Science ®Google Scholar
• BrobergerCMcCormickDAExcitatory effects of thyrotropin- releasing hormone in the thalamusJ Neurosci20052571664167315716402
   PubMed Web of Science ®Google Scholar
• KhomaneKSMeenaCLJainRBansalAKNovel thyrotropin-releasing hormone analogs: a patent reviewExpert Opin Ther Pat201121111673169122017410
   PubMed Web of Science ®Google Scholar
• ReddingTWSchallyAVOn the half life of thyrotropin-releasing hormone in ratsNeuroendocrinology1972942502564622720
   PubMed Web of Science ®Google Scholar
• MongaVMeenaCRajputSSynthesis, receptor binding, and CNS pharmacological studies of new thyrotropin-releasing hormone (TRH) analoguesChemMedChem20116353154321302359
   PubMed Web of Science ®Google Scholar
• NishinoSArrigoniJSheltonJKanbayashiTDementWCMignotEEffects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsyJ Neurosci19971716640164089236248
   PubMed Web of Science ®Google Scholar
• RiehlJHondaKKwanMHongJMignotENishinoSChronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsyNeuropsychopharmacology2000231344510869884
   PubMed Web of Science ®Google Scholar
• MongaVMeenaCLKaurNJainRChemistry and biology of thyrotropin-releasing hormone (TRH) and its analogsCurr Med Chem200815262718273318991632
   PubMed Web of Science ®Google Scholar
• ThirunarayananNNirEARaakaBMGershengornMCThyrotropin-releasing hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin actions in the CNS of miceNeuropsychopharmacology201338695095623303050
   PubMed Web of Science ®Google Scholar
• ThirunarayananNRaakaBMGershengornMCTaltirelin is a superagonist at the human thyrotropin-releasing hormone receptorFront Endocrinol (Lausanne)2012312023087672
   PubMedGoogle Scholar
• AsaiHAsahiTYamamuraMYamauchi-KohnoRSaitoALack of behavioral tolerance by repeated treatment with taltirelin hydrate, a thyrotropin-releasing hormone analog, in ratsPharmacol Biochem Behav200582464665116368129
   PubMed Web of Science ®Google Scholar
• HaraJGerashchenkoDWisorJPSakuraiTXieXKilduffTSThyrotropin- releasing hormone increases behavioral arousal through modulation of hypocretin/orexin neuronsJ Neurosci200929123705371419321767
   PubMed Web of Science ®Google Scholar
• GonzálezJAHorjales-AraujoEFuggerLBrobergerCBurdakovDStimulation of orexin/hypocretin neurones by thyrotropin-releasing hormoneJ Physiol2009587Pt 61179118619204048
   PubMed Web of Science ®Google Scholar
• ParmentierRKolbaevSKlyuchBPExcitation of histaminergic tuberomamillary neurons by thyrotropin-releasing hormoneJ Neurosci200929144471448319357273
   PubMed Web of Science ®Google Scholar
• ZhangXvan den PolANThyrotropin-releasing hormone (TRH) inhibits melanin-concentrating hormone neurons: implications for TRH-mediated anorexic and arousal actionsJ Neurosci20123293032304322378876
   PubMed Web of Science ®Google Scholar
• HallmayerJFaracoJLinLNarcolepsy is strongly associated with the T-cell receptor alpha locusNat Genet20094170871119412176
   PubMed Web of Science ®Google Scholar
• HorHKutalikZDauvilliersYGenome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsyNat Genet20104278678920711174
   PubMed Web of Science ®Google Scholar
• Cvetkovic-LopesVBayerLDorsazSElevated Tribbles homolog 2-specific antibody levels in narcolepsy patientsJ Clin Invest201012071371920160349
   PubMed Web of Science ®Google Scholar
• ToyodaHTanakaSMiyagawaTHondaYTokynagaKHondaMAnti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsySleep20103387587820614847
   PubMed Web of Science ®Google Scholar
• KawashimaMLinLTanakaSAnti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexySleep20103386987420614846
   PubMed Web of Science ®Google Scholar
• LimASScammellTEThe trouble with Tribbles: do antibodies against TRIB2 cause narcolepsy?Sleep201033785785820614841
   PubMed Web of Science ®Google Scholar
• HanFLinLWarbySCNarcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in ChinaAnn Neurol20117041041721866560
   PubMed Web of Science ®Google Scholar
• PartinenMSaarenpää-HeikkiläOIlveskoskiIIncreased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in FinlandPLoS One20127e3372322470463
   PubMed Web of Science ®Google Scholar
• HeierMSGautvikKMWannagEIncidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza ASleep Med20131486787123773727
   PubMed Web of Science ®Google Scholar
• AhmedSSSchurPHMacDonaldNESteinmanLNarcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvantsJ Autoimmun20145011124559657
   PubMed Web of Science ®Google Scholar
• ValkoPOKhatamiRBaumannCRBassettiCLNo persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexyJ Neurol2008255121900190318825431
   PubMed Web of Science ®Google Scholar
• PlazziGPoliFFranceschiniCIntravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexyJ Neurol2008255101549155418769859
   PubMed Web of Science ®Google Scholar
• DauvilliersYCarlanderBRivierFTouchonJTaftiMSuccessful management of cataplexy with intravenous immunoglobulins shortly after narcolepsy onsetAnn Neurol20045690590815562415
   PubMed Web of Science ®Google Scholar
• DauvilliersYFollow-up of four narcolepsy patients treated with intravenous immunoglobulinsAnn Neurol200660115316802296
   PubMed Web of Science ®Google Scholar
• LecendreuxMMaretSBassettiCMourenMCTaftiMClinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boyJ Sleep Res200312434734814633248
   PubMed Web of Science ®Google Scholar
• ZuberiSMMignotELingLVariable response to intravenous immunoglobulin therapy in childhood narcolepsyJ Sleep Res200413Suppl 1828 Abstract
   Google Scholar
• ChenWBlackJCallPMignotELate-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresisAnn Neurol200558348949016130098
   PubMed Web of Science ®Google Scholar
• ThannickalTCMooreRYNienhuisRReduced number of hypocretin neurons in human narcolepsyNeuron200027346947411055430
   PubMed Web of Science ®Google Scholar
• DonjacourCELammersGJA remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexyJ Sleep Res201221447948022142323
   PubMed Web of Science ®Google Scholar
• Sabatos-PeytonCAVerhagenJWraithDCAntigen-specific immunotherapy of autoimmune and allergic diseasesCurr Opin Immunol201022560961520850958
   PubMed Web of Science ®Google Scholar
• HasanSPradervandSAhnaouADrinkenburgWTaftiMFrankenPHow to keep the brain awake? The complex molecular pharmacogenetics of wake promotionNeuropsychopharmacology20093471625164019194377
   PubMed Web of Science ®Google Scholar
• AmsterdamJDBrunswickDJHundertMA single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A – a putative, new antidepressantProg Neuropsychopharmacol Biol Psychiatry2002267–81333133812502022
   PubMed Web of Science ®Google Scholar
• BlackJSwickTFeldmanNEfficacy and safety of oral ADX-N05 for the treatment of excessive daytime sleepiness in adults with narcolepsy: results of a randomized, double-blind, placebo-controlled trial [abstract]Presented at: 28th Annual Meeting of the Associated Professional Sleep Societies (SLEEP)May 31–June 4, 2014Minneapolis, MN Abstract LBA4
   Google Scholar